Prosight Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Prosight Management reported a $580M portfolio of 36 positions to the SEC as of the end of Q2 2026. Its largest positions are LKFT, JANX, NKTR. During the quarter it opened Insmed and Mineralys Therapeutics and exited Concentra Group Holdings Parent and Phreesia.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Prosight Management has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Stake reported in the company · event of Jun 30, 2026 · filed Aug 10, 2026 · filing ↗
What changed this quarter
50 positions with a change (5 new, 16 added to, 15 trimmed, 14 sold); also, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Insmed+6.6 ppof portfolioNew— → 6.9%
- PROCEPT BioRobotics−86%fewer sharesReduced8.0% → 1.0%
- GeneDx Holdings−84%fewer sharesReduced5.5% → 1.0%
- MeiraGTx Holdings−97%fewer sharesReduced3.7% → 0.2%
- Boston Scientific+60%more sharesIncreased8.2% → 9.3%
- iRhythm Holdings+1,555%more sharesIncreased0.2% → 3.4%
- Lakefront Biotherapeutics+32%more sharesIncreased7.6% → 10.6%
- Kura Oncology−40%fewer sharesReduced4.5% → 3.8%
- Mineralys Therapeutics+2.0 ppof portfolioNew— → 2.1%
- Concentra Group Holdings Parent−1.8 ppof portfolioSold out1.8% → —
- Syndax Pharmaceuticals+56%more sharesIncreased2.9% → 4.5%
- Phreesia−1.5 ppof portfolioSold out1.5% → —
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Lakefront BiotherapeuticsLKFT10.6%
- Janux TherapeuticsJANX10.1%
- Nektar TherapeuticsNKTR9.7%
- Boston ScientificBSX9.3%
- Shattuck LabsSTTK7.1%
- InsmedINSM6.9%
- Alnylam PharmaceuticalsALNY5.1%
- Syndax PharmaceuticalsSNDX4.5%
- KURA OncologyKURA3.8%
- Alkermes plc.ALKS3.6%
- iRhythm HoldingsIRTC3.4%
- Veeva SystemsVEEV3.2%
- ZymeworksZYME3.0%
- AbivaxABVX2.5%
- Crinetics PharmaceuticalsCRNX2.4%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 36
Q2 2026: 71%
Q2 2026: 27.7%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 30, 2026 (high confidence).
The data, as reported: PROSIGHT CAPITAL (CRD 148791): 7.B private funds: 2 hedge (gross assets $278M); 5.D assets by client type: pooled vehicles 100% (of $1.0 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Global Frontier InvestmentsInvestment firm · $581M
- Land & Buildings Investment ManagementInvestment firm · $583M
- Sio Capital ManagementInvestment firm · $584M
- Nuance InvestmentsInvestment firm · $588M
- Solel PartnersInvestment firm · $588M
- De Burlo GroupInvestment firm · $569M